Arrail Group (I1D) 주식 개요아레일 그룹 유한회사는 중국에서 치과 병원과 클리닉을 운영하고 있습니다. 자세히 보기I1D 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장0/6과거 실적3/6재무 건전성5/6배당0/6강점공정 가치 추정치보다 낮은 48.2% 에서 거래지난 1년간 수익이 28.1% 증가했습니다.위험 분석주식은 유동성이 매우 낮습니다최신 재무 보고서가 6개월 이상 지났습니다.재무 결과에 영향을 미치는 대규모 일회성 항목지난 1년 동안 주주가 희석되었습니다.모든 위험 점검 보기I1D Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW480,107 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA480,107 investors already sharing narrativesYour Fair Value€Current Price€0.2010.0% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-701m2b2016201920222025202620282031Revenue CN¥2.1bEarnings CN¥27.8mAdvancedSet Fair ValueView all narrativesArrail Group Limited 경쟁사MEDICLINSymbol: XTRA:MEDMarket cap: €195.7mLIMES SchlossklinikenSymbol: XTRA:LIKMarket cap: €163.9mFresenius Medical CareSymbol: XTRA:FMEMarket cap: €11.4bMediosSymbol: XTRA:ILM1Market cap: €307.3m가격 이력 및 성과Arrail Group 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가HK$0.2052주 최고가HK$0.3352주 최저가HK$0.17베타0.261개월 변동0%3개월 변동1.54%1년 변동-31.72%3년 변동-87.85%5년 변동n/aIPO 이후 변동-87.23%최근 뉴스 및 업데이트공고 • Jun 30Arrail Group Limited to Report Fiscal Year 2026 Results on Jun 30, 2026Arrail Group Limited announced that they will report fiscal year 2026 results at 12:30 PM, China Standard Time on Jun 30, 2026공고 • Nov 18Arrail Group Limited to Report First Half, 2026 Results on Nov 28, 2025Arrail Group Limited announced that they will report first half, 2026 results on Nov 28, 2025공고 • Jun 28Arrail Group Limited, Annual General Meeting, Sep 26, 2025Arrail Group Limited, Annual General Meeting, Sep 26, 2025.공고 • Jun 17Arrail Group Limited to Report Fiscal Year 2025 Results on Jun 27, 2025Arrail Group Limited announced that they will report fiscal year 2025 results on Jun 27, 2025공고 • Nov 19Arrail Group Limited to Report Q2, 2025 Results on Nov 29, 2024Arrail Group Limited announced that they will report Q2, 2025 results on Nov 29, 2024공고 • Sep 26Arrail Group Limited Announces the Retirement of Xin Qin Jessie as Executive DirectorArrail Group Limited announced that Ms. Xin Qin Jessie retired as an executive Director at the conclusion of the AGM held on September 26, 2024, in order to focus on her management commitment as the chief financial officer of the Group.더 많은 업데이트 보기Recent updates공고 • Jun 30Arrail Group Limited to Report Fiscal Year 2026 Results on Jun 30, 2026Arrail Group Limited announced that they will report fiscal year 2026 results at 12:30 PM, China Standard Time on Jun 30, 2026공고 • Nov 18Arrail Group Limited to Report First Half, 2026 Results on Nov 28, 2025Arrail Group Limited announced that they will report first half, 2026 results on Nov 28, 2025공고 • Jun 28Arrail Group Limited, Annual General Meeting, Sep 26, 2025Arrail Group Limited, Annual General Meeting, Sep 26, 2025.공고 • Jun 17Arrail Group Limited to Report Fiscal Year 2025 Results on Jun 27, 2025Arrail Group Limited announced that they will report fiscal year 2025 results on Jun 27, 2025공고 • Nov 19Arrail Group Limited to Report Q2, 2025 Results on Nov 29, 2024Arrail Group Limited announced that they will report Q2, 2025 results on Nov 29, 2024공고 • Sep 26Arrail Group Limited Announces the Retirement of Xin Qin Jessie as Executive DirectorArrail Group Limited announced that Ms. Xin Qin Jessie retired as an executive Director at the conclusion of the AGM held on September 26, 2024, in order to focus on her management commitment as the chief financial officer of the Group.Reported Earnings • Jul 28Full year 2024 earnings released: EPS: CN¥0.037 (vs CN¥0.38 loss in FY 2023)Full year 2024 results: EPS: CN¥0.037 (up from CN¥0.38 loss in FY 2023). Revenue: CN¥1.75b (up 19% from FY 2023). Net income: CN¥17.2m (up CN¥237.1m from FY 2023). Profit margin: 1.0% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany.Recent Insider Transactions • Jul 05Chairman of the Board & CEO recently bought €217k worth of stockOn the 28th of June, Qifang Zou bought around 350k shares on-market at roughly €0.62 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Qifang has been a buyer over the last 12 months, purchasing a net total of €451k worth in shares.공고 • Jun 27Arrail Group Limited, Annual General Meeting, Sep 26, 2024Arrail Group Limited, Annual General Meeting, Sep 26, 2024.Reported Earnings • Jun 27Full year 2024 earnings released: EPS: CN¥0.04 (vs CN¥0.38 loss in FY 2023)Full year 2024 results: EPS: CN¥0.04 (up from CN¥0.38 loss in FY 2023). Revenue: CN¥1.75b (up 19% from FY 2023). Net income: CN¥17.2m (up CN¥237.1m from FY 2023). Profit margin: 1.0% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany.공고 • Jun 21Arrail Group Limited Provides Earnings Guidance for the Fiscal Year Ended March 31, 2024Arrail Group Limited provided earnings guidance for the fiscal year ended March 31, 2024. For the year, the Group is expected to record a net profit of no less than RMB 10.0 million for the fiscal year ended March 31, 2024, as compared to the net loss of approximately RMB 223.3 million for the fiscal year ended March 31, 2023. The expected profit is mainly attributable to revenue increase from business recovery after COVID-19 and the increase in the number of patient visits, especially the increased revenue generated from general dentistry, and operating improvement.공고 • Jun 15Arrail Group Limited to Report Fiscal Year 2024 Results on Jun 26, 2024Arrail Group Limited announced that they will report fiscal year 2024 results on Jun 26, 2024Recent Insider Transactions • May 02Chairman of the Board & CEO recently bought €73k worth of stockOn the 26th of April, Qifang Zou bought around 100k shares on-market at roughly €0.73 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Qifang has been a buyer over the last 12 months, purchasing a net total of €228k worth in shares.Recent Insider Transactions • Dec 19Chairman of the Board & CEO recently sold €4.8m worth of stockOn the 12th of December, Qifang Zou sold around 3m shares on-market at roughly €1.56 per share. This transaction amounted to 4.4% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Qifang has been a net seller over the last 12 months, reducing personal holdings by €4.7m.Reported Earnings • Nov 30First half 2024 earnings released: EPS: CN¥0.011 (vs CN¥0.15 loss in 1H 2023)First half 2024 results: EPS: CN¥0.011 (up from CN¥0.15 loss in 1H 2023). Revenue: CN¥886.2m (up 15% from 1H 2023). Net income: CN¥4.98m (up CN¥93.6m from 1H 2023). Profit margin: 0.6% (up from net loss in 1H 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 1.6% decline forecast for the Healthcare industry in Germany.공고 • Nov 24Arrail Group Limited Announces Unaudited Consolidated Earnings Guidance for the Six Months Ended September 30, 2023The board (the "Board") of directors (the "Director(s)") of Arrail Group Limited announced that based on a preliminary review of the unaudited consolidated management accounts of the Group for the six months ended September 30, 2023 and assessment of the latest information currently available to the Board, the Group is expected to record a net profit of no less than RMB 5.0 million for the six months ended September 30, 2023, as compared to the net loss of approximately RMB 90.0 million for the six months ended September 30, 2022. The expected profit is mainly attributable to the business recovery after COVID-19 and operating improvement.공고 • Nov 17Arrail Group Limited to Report First Half, 2024 Results on Nov 28, 2023Arrail Group Limited announced that they will report first half, 2024 results on Nov 28, 2023New Risk • Oct 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 8.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.Breakeven Date Change • Sep 26Forecast breakeven date moved forward to 2024The 3 analysts covering Arrail Group previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of CN¥29.4m in 2024. Earnings growth of 94% is required to achieve expected profit on schedule.Reported Earnings • Jul 28Full year 2023 earnings released: CN¥0.38 loss per share (vs CN¥8.70 loss in FY 2022)Full year 2023 results: CN¥0.38 loss per share (improved from CN¥8.70 loss in FY 2022). Revenue: CN¥1.47b (down 9.2% from FY 2022). Net loss: CN¥219.9m (loss narrowed 69% from FY 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany.Recent Insider Transactions • Jul 26Chairman of the Board & CEO recently bought €164k worth of stockOn the 19th of July, Qifang Zou bought around 200k shares on-market at roughly €0.82 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Qifang has been a buyer over the last 12 months, purchasing a net total of €162k worth in shares.Breakeven Date Change • Jul 14Forecast breakeven date pushed back to 2025The 3 analysts covering Arrail Group previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 96% to 2024. The company is expected to make a profit of CN¥84.9m in 2025. Average annual earnings growth of 104% is required to achieve expected profit on schedule.공고 • Jun 28Arrail Group Limited, Annual General Meeting, Sep 26, 2023Arrail Group Limited, Annual General Meeting, Sep 26, 2023.Reported Earnings • Jun 28Full year 2023 earnings released: CN¥0.38 loss per share (vs CN¥8.70 loss in FY 2022)Full year 2023 results: CN¥0.38 loss per share (improved from CN¥8.70 loss in FY 2022). Revenue: CN¥1.47b (down 9.2% from FY 2022). Net loss: CN¥219.9m (loss narrowed 69% from FY 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Healthcare industry in Germany.공고 • Jun 15Arrail Group Limited to Report Fiscal Year 2023 Results on Jun 27, 2023Arrail Group Limited announced that they will report fiscal year 2023 results on Jun 27, 2023Buying Opportunity • Apr 24Now 32% undervaluedOver the last 90 days, the stock is up 12%. The fair value is estimated to be €1.78, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.0% over the last year. Earnings per share has grown by 92%.Breakeven Date Change • Feb 28Forecast breakeven date pushed back to 2024The 3 analysts covering Arrail Group previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 95% to 2023. The company is expected to make a profit of CN¥103.4m in 2024. Average annual earnings growth of 108% is required to achieve expected profit on schedule.Buying Opportunity • Feb 25Now 21% undervaluedOver the last 90 days, the stock is up 84%. The fair value is estimated to be €1.78, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.0% over the last year. Earnings per share has grown by 92%.Reported Earnings • Jan 01First half 2023 earnings released: CN¥0.15 loss per share (vs CN¥5.89 loss in 1H 2022)First half 2023 results: CN¥0.15 loss per share (improved from CN¥5.89 loss in 1H 2022). Revenue: CN¥771.6m (down 8.3% from 1H 2022). Net loss: CN¥88.6m (loss narrowed 81% from 1H 2022). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Healthcare industry in Germany.Reported Earnings • Nov 30First half 2023 earnings releasedFirst half 2023 results: Revenue: CN¥771.6m (down 8.3% from 1H 2022). Net loss: CN¥88.6m (loss narrowed 81% from 1H 2022). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Germany.Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Michelle Liu was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Reported Earnings • Jul 30Full year 2022 earnings released: CN¥8.70 loss per share (vs CN¥8.21 loss in FY 2021)Full year 2022 results: CN¥8.70 loss per share (down from CN¥8.21 loss in FY 2021). Revenue: CN¥1.62b (up 7.2% from FY 2021). Net loss: CN¥701.0m (loss widened 17% from FY 2021). Over the next year, revenue is forecast to grow 19%, compared to a 3.8% growth forecast for the industry in Germany.Reported Earnings • Jun 29Full year 2022 earnings released: CN¥8.70 loss per share (vs CN¥205 loss in FY 2021)Full year 2022 results: CN¥8.70 loss per share. Revenue: CN¥1.62b (up 7.2% from FY 2021). Net loss: CN¥701.0m (loss widened 17% from FY 2021). Over the next year, revenue is forecast to grow 22%, compared to a 4.3% growth forecast for the industry in Germany.Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Michelle Liu was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Board Change • Apr 12Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Michelle Liu was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.주주 수익률I1DDE HealthcareDE 시장7D0%3.1%0.1%1Y-31.7%1.0%-0.5%전체 주주 수익률 보기수익률 대 산업: I1D은 지난 1년 동안 1%의 수익을 기록한 German Healthcare 산업보다 저조한 성과를 냈습니다.수익률 대 시장: I1D은 지난 1년 동안 -0.5%를 기록한 German 시장보다 저조한 성과를 냈습니다.주가 변동성Is I1D's price volatile compared to industry and market?I1D volatilityI1D Average Weekly Movementn/aHealthcare Industry Average Movement5.1%Market Average Movement5.3%10% most volatile stocks in DE Market12.7%10% least volatile stocks in DE Market2.7%안정적인 주가: I1D의 주가는 지난 3개월 동안 German 시장보다 변동성이 컸습니다.시간에 따른 변동성: Insufficient data to determine I1D의 변동성 변화를 판단할 수 없습니다.회사 소개설립직원 수CEO웹사이트19993,111Robert Zouwww.arrailgroup.com아레일 그룹은 중국에서 치과 병원과 클리닉을 운영하고 있습니다. 이 회사는 일반 치과, 치아 교정, 임플란트 등의 치과 서비스를 제공합니다. 또한 의료 재료 도매업과 병원 관리 사업에도 종사하고 있습니다.더 보기Arrail Group Limited 기초 지표 요약Arrail Group의 순이익과 매출은 시가총액과 어떻게 비교됩니까?I1D 기초 통계시가총액€111.22m순이익 (TTM)€2.71m매출 (TTM)€208.26m41.0x주가수익비율(P/E)0.5x주가매출비율(P/S)I1D는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표I1D 손익계산서 (TTM)매출CN¥1.69b매출원가CN¥1.35b총이익CN¥342.09m기타 비용CN¥320.10m순이익CN¥21.99m최근 보고된 실적Mar 31, 2025다음 실적 발표일해당 없음주당순이익(EPS)0.039총이익률20.26%순이익률1.30%부채/자본 비율24.8%I1D의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/02/28 03:07종가2025/12/01 00:00수익2025/03/31연간 수익2025/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Arrail Group Limited는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Yanyin ZhuChina International Capital Corporation LimitedYoujue HuMorgan Stanley
공고 • Jun 30Arrail Group Limited to Report Fiscal Year 2026 Results on Jun 30, 2026Arrail Group Limited announced that they will report fiscal year 2026 results at 12:30 PM, China Standard Time on Jun 30, 2026
공고 • Nov 18Arrail Group Limited to Report First Half, 2026 Results on Nov 28, 2025Arrail Group Limited announced that they will report first half, 2026 results on Nov 28, 2025
공고 • Jun 28Arrail Group Limited, Annual General Meeting, Sep 26, 2025Arrail Group Limited, Annual General Meeting, Sep 26, 2025.
공고 • Jun 17Arrail Group Limited to Report Fiscal Year 2025 Results on Jun 27, 2025Arrail Group Limited announced that they will report fiscal year 2025 results on Jun 27, 2025
공고 • Nov 19Arrail Group Limited to Report Q2, 2025 Results on Nov 29, 2024Arrail Group Limited announced that they will report Q2, 2025 results on Nov 29, 2024
공고 • Sep 26Arrail Group Limited Announces the Retirement of Xin Qin Jessie as Executive DirectorArrail Group Limited announced that Ms. Xin Qin Jessie retired as an executive Director at the conclusion of the AGM held on September 26, 2024, in order to focus on her management commitment as the chief financial officer of the Group.
공고 • Jun 30Arrail Group Limited to Report Fiscal Year 2026 Results on Jun 30, 2026Arrail Group Limited announced that they will report fiscal year 2026 results at 12:30 PM, China Standard Time on Jun 30, 2026
공고 • Nov 18Arrail Group Limited to Report First Half, 2026 Results on Nov 28, 2025Arrail Group Limited announced that they will report first half, 2026 results on Nov 28, 2025
공고 • Jun 28Arrail Group Limited, Annual General Meeting, Sep 26, 2025Arrail Group Limited, Annual General Meeting, Sep 26, 2025.
공고 • Jun 17Arrail Group Limited to Report Fiscal Year 2025 Results on Jun 27, 2025Arrail Group Limited announced that they will report fiscal year 2025 results on Jun 27, 2025
공고 • Nov 19Arrail Group Limited to Report Q2, 2025 Results on Nov 29, 2024Arrail Group Limited announced that they will report Q2, 2025 results on Nov 29, 2024
공고 • Sep 26Arrail Group Limited Announces the Retirement of Xin Qin Jessie as Executive DirectorArrail Group Limited announced that Ms. Xin Qin Jessie retired as an executive Director at the conclusion of the AGM held on September 26, 2024, in order to focus on her management commitment as the chief financial officer of the Group.
Reported Earnings • Jul 28Full year 2024 earnings released: EPS: CN¥0.037 (vs CN¥0.38 loss in FY 2023)Full year 2024 results: EPS: CN¥0.037 (up from CN¥0.38 loss in FY 2023). Revenue: CN¥1.75b (up 19% from FY 2023). Net income: CN¥17.2m (up CN¥237.1m from FY 2023). Profit margin: 1.0% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany.
Recent Insider Transactions • Jul 05Chairman of the Board & CEO recently bought €217k worth of stockOn the 28th of June, Qifang Zou bought around 350k shares on-market at roughly €0.62 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Qifang has been a buyer over the last 12 months, purchasing a net total of €451k worth in shares.
공고 • Jun 27Arrail Group Limited, Annual General Meeting, Sep 26, 2024Arrail Group Limited, Annual General Meeting, Sep 26, 2024.
Reported Earnings • Jun 27Full year 2024 earnings released: EPS: CN¥0.04 (vs CN¥0.38 loss in FY 2023)Full year 2024 results: EPS: CN¥0.04 (up from CN¥0.38 loss in FY 2023). Revenue: CN¥1.75b (up 19% from FY 2023). Net income: CN¥17.2m (up CN¥237.1m from FY 2023). Profit margin: 1.0% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany.
공고 • Jun 21Arrail Group Limited Provides Earnings Guidance for the Fiscal Year Ended March 31, 2024Arrail Group Limited provided earnings guidance for the fiscal year ended March 31, 2024. For the year, the Group is expected to record a net profit of no less than RMB 10.0 million for the fiscal year ended March 31, 2024, as compared to the net loss of approximately RMB 223.3 million for the fiscal year ended March 31, 2023. The expected profit is mainly attributable to revenue increase from business recovery after COVID-19 and the increase in the number of patient visits, especially the increased revenue generated from general dentistry, and operating improvement.
공고 • Jun 15Arrail Group Limited to Report Fiscal Year 2024 Results on Jun 26, 2024Arrail Group Limited announced that they will report fiscal year 2024 results on Jun 26, 2024
Recent Insider Transactions • May 02Chairman of the Board & CEO recently bought €73k worth of stockOn the 26th of April, Qifang Zou bought around 100k shares on-market at roughly €0.73 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Qifang has been a buyer over the last 12 months, purchasing a net total of €228k worth in shares.
Recent Insider Transactions • Dec 19Chairman of the Board & CEO recently sold €4.8m worth of stockOn the 12th of December, Qifang Zou sold around 3m shares on-market at roughly €1.56 per share. This transaction amounted to 4.4% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Qifang has been a net seller over the last 12 months, reducing personal holdings by €4.7m.
Reported Earnings • Nov 30First half 2024 earnings released: EPS: CN¥0.011 (vs CN¥0.15 loss in 1H 2023)First half 2024 results: EPS: CN¥0.011 (up from CN¥0.15 loss in 1H 2023). Revenue: CN¥886.2m (up 15% from 1H 2023). Net income: CN¥4.98m (up CN¥93.6m from 1H 2023). Profit margin: 0.6% (up from net loss in 1H 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 1.6% decline forecast for the Healthcare industry in Germany.
공고 • Nov 24Arrail Group Limited Announces Unaudited Consolidated Earnings Guidance for the Six Months Ended September 30, 2023The board (the "Board") of directors (the "Director(s)") of Arrail Group Limited announced that based on a preliminary review of the unaudited consolidated management accounts of the Group for the six months ended September 30, 2023 and assessment of the latest information currently available to the Board, the Group is expected to record a net profit of no less than RMB 5.0 million for the six months ended September 30, 2023, as compared to the net loss of approximately RMB 90.0 million for the six months ended September 30, 2022. The expected profit is mainly attributable to the business recovery after COVID-19 and operating improvement.
공고 • Nov 17Arrail Group Limited to Report First Half, 2024 Results on Nov 28, 2023Arrail Group Limited announced that they will report first half, 2024 results on Nov 28, 2023
New Risk • Oct 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 8.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
Breakeven Date Change • Sep 26Forecast breakeven date moved forward to 2024The 3 analysts covering Arrail Group previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of CN¥29.4m in 2024. Earnings growth of 94% is required to achieve expected profit on schedule.
Reported Earnings • Jul 28Full year 2023 earnings released: CN¥0.38 loss per share (vs CN¥8.70 loss in FY 2022)Full year 2023 results: CN¥0.38 loss per share (improved from CN¥8.70 loss in FY 2022). Revenue: CN¥1.47b (down 9.2% from FY 2022). Net loss: CN¥219.9m (loss narrowed 69% from FY 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany.
Recent Insider Transactions • Jul 26Chairman of the Board & CEO recently bought €164k worth of stockOn the 19th of July, Qifang Zou bought around 200k shares on-market at roughly €0.82 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Qifang has been a buyer over the last 12 months, purchasing a net total of €162k worth in shares.
Breakeven Date Change • Jul 14Forecast breakeven date pushed back to 2025The 3 analysts covering Arrail Group previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 96% to 2024. The company is expected to make a profit of CN¥84.9m in 2025. Average annual earnings growth of 104% is required to achieve expected profit on schedule.
공고 • Jun 28Arrail Group Limited, Annual General Meeting, Sep 26, 2023Arrail Group Limited, Annual General Meeting, Sep 26, 2023.
Reported Earnings • Jun 28Full year 2023 earnings released: CN¥0.38 loss per share (vs CN¥8.70 loss in FY 2022)Full year 2023 results: CN¥0.38 loss per share (improved from CN¥8.70 loss in FY 2022). Revenue: CN¥1.47b (down 9.2% from FY 2022). Net loss: CN¥219.9m (loss narrowed 69% from FY 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Healthcare industry in Germany.
공고 • Jun 15Arrail Group Limited to Report Fiscal Year 2023 Results on Jun 27, 2023Arrail Group Limited announced that they will report fiscal year 2023 results on Jun 27, 2023
Buying Opportunity • Apr 24Now 32% undervaluedOver the last 90 days, the stock is up 12%. The fair value is estimated to be €1.78, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.0% over the last year. Earnings per share has grown by 92%.
Breakeven Date Change • Feb 28Forecast breakeven date pushed back to 2024The 3 analysts covering Arrail Group previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 95% to 2023. The company is expected to make a profit of CN¥103.4m in 2024. Average annual earnings growth of 108% is required to achieve expected profit on schedule.
Buying Opportunity • Feb 25Now 21% undervaluedOver the last 90 days, the stock is up 84%. The fair value is estimated to be €1.78, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.0% over the last year. Earnings per share has grown by 92%.
Reported Earnings • Jan 01First half 2023 earnings released: CN¥0.15 loss per share (vs CN¥5.89 loss in 1H 2022)First half 2023 results: CN¥0.15 loss per share (improved from CN¥5.89 loss in 1H 2022). Revenue: CN¥771.6m (down 8.3% from 1H 2022). Net loss: CN¥88.6m (loss narrowed 81% from 1H 2022). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Healthcare industry in Germany.
Reported Earnings • Nov 30First half 2023 earnings releasedFirst half 2023 results: Revenue: CN¥771.6m (down 8.3% from 1H 2022). Net loss: CN¥88.6m (loss narrowed 81% from 1H 2022). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Germany.
Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Michelle Liu was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Reported Earnings • Jul 30Full year 2022 earnings released: CN¥8.70 loss per share (vs CN¥8.21 loss in FY 2021)Full year 2022 results: CN¥8.70 loss per share (down from CN¥8.21 loss in FY 2021). Revenue: CN¥1.62b (up 7.2% from FY 2021). Net loss: CN¥701.0m (loss widened 17% from FY 2021). Over the next year, revenue is forecast to grow 19%, compared to a 3.8% growth forecast for the industry in Germany.
Reported Earnings • Jun 29Full year 2022 earnings released: CN¥8.70 loss per share (vs CN¥205 loss in FY 2021)Full year 2022 results: CN¥8.70 loss per share. Revenue: CN¥1.62b (up 7.2% from FY 2021). Net loss: CN¥701.0m (loss widened 17% from FY 2021). Over the next year, revenue is forecast to grow 22%, compared to a 4.3% growth forecast for the industry in Germany.
Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Michelle Liu was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Board Change • Apr 12Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Michelle Liu was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
